New imaging agent could spot hidden breast cancer spread

NCT ID NCT04758780

Completed Diagnosis Sponsor: Institut Cancerologie de l'Ouest Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jul 21, 2026 · Updated 2 times

Summary

This study tested a new radioactive tracer called 89Zr-TLX250 for PET scans in 12 people with metastatic triple negative breast cancer. The goal was to see if it could find more tumors than the standard FDG PET scan, especially in the brain. Researchers compared the number of lesions detected by each scan to see if the new tracer is more sensitive.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: 89Zr-TLX250 (a radioactive tracer for PET scans)
What this could lead to: If successful, this could lead to a more accurate imaging method for detecting metastatic triple negative breast cancer, especially in the brain.
What could go wrong: This is a small, early-phase study with only 12 participants, so results may not apply to everyone. The new tracer may not prove better than existing scans.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for TRIPLE NEGATIVE BREAST CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

triple-negative breast carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

TRIPLE NEGATIVE BREAST CANCER

Contacts and locations

Locations

ICO René Gauducheau

Saint-Herblain, 44805, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.